Asana’s mission is to develop novel and clinically differentiated products that address unmet clinical needs and provide new treatment options to physicians and patients.
Asana BioSciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel targeted therapies in inflammation/immunology and oncology.
Asana’s proprietary portfolio comprises multiple drug candidates, both small molecules and biologics (antibody-drug conjugate). Our inflammation and immunology assets are being studied in indications such as chronic hand eczema and atopic dermatitis and also have applications in many other immunological diseases. Our oncology assets target advanced or metastatic cancers, including melanoma, non-small cell lung cancer, colorectal cancer and other solid tumors.
Asana BioSciences was founded in 2014 and is based near Princeton, NJ.